keyword
MENU ▼
Read by QxMD icon Read
search

Entecavir

keyword
https://www.readbyqxmd.com/read/28919358/perfused-human-hepatocyte-microtissues-identify-reactive-metabolite-forming-and-mitochondria-perturbing-hepatotoxins
#1
Cliff Rowe, Mohsen Shaeri, Emma Large, Terri Cornforth, Angela Robinson, Tomasz Kostrzewski, Rowena Sison-Young, Christopher Goldring, Kevin Park, David Hughes
Hepatotoxins cause liver damage via many mechanisms but the formation of reactive metabolites and/or damage to liver mitochondria are commonly implicated. We assess 3D human primary hepatocyte microtissues as a platform for hepatotoxicity studies with reactive metabolite-forming and mitochondria-perturbing compounds. We show that microtissues formed from cryopreserved human hepatocytes had bile canaliculi, transcribed mRNA from genes associated with xenobiotic metabolism and expressed functional cytochrome P450 enzymes...
September 15, 2017: Toxicology in Vitro: An International Journal Published in Association with BIBRA
https://www.readbyqxmd.com/read/28895260/changes-of-serum-chitinase-3-like-1-levels-correlate-with-changes-of-liver-fibrosis-measured-by-the-two-established-quantitative-methods-in-chronic-hepatitis-b-patients-following-antiviral-therapy
#2
Lin Wang, Tianhui Liu, Jialing Zhou, Hong You, Jidong Jia
AIM: Non-invasive assessment for liver fibrosis change is still an unmet medical need in the era of antiviral therapy. Therefore, we explore whether the chitinase 3-like 1 (CHI3L1), a serum marker of liver fibrosis, can be used as a non-invasive surrogate marker to fibrosis change during treatment. METHODS: We correlated the serum CHI3L1 levels with liver tissue collagen proportionate area (CPA) in a cohort of 131 CHB patients receiving entecavir-based antiviral therapy for 78 weeks...
September 12, 2017: Hepatology Research: the Official Journal of the Japan Society of Hepatology
https://www.readbyqxmd.com/read/28889724/effects-of-the-combined-administration-of-entecavir-and-adefovir-dipivoxil-to-improve-hepatic-fibrosis-in-hepatitis-b-patients-with-interferon-resistance
#3
Yuqiu Sun, Keqin Wu, Fei Shen, Ling Qiu, Binhe Chen, Lijun Yu, Shuzhen Chang
OBJECTIVE: To observe the effect of the combined administration of entecavir and adefovir dipivoxil to improve hepatic fibrosis in hepatitis B patients with interferon resistance. PATIENTS AND METHODS: This study comprised 90 hepatitis B patients with hepatic fibrosis and interferon (IFN) resistance who were admitted in the hospital's department of infectious disease for diagnosis and treatment between January 2013 and September 2015. They were randomly divided into two groups in accordance with the random number table: (1) the combination treatment group (n = 45), and (2) the entecavir group (n = 45)...
September 8, 2017: Minerva Medica
https://www.readbyqxmd.com/read/28881690/perioperative-entecavir-for-patients-with-hbv-related-hepatocellular-carcinoma-and-low-levels-of-viral-dna-analysis-using-propensity-score-matching
#4
Bao-Hong Yuan, Ru-Hong Li, Wei-Ping Yuan, Bang-De Xiang, Ming-Hua Zheng, Tian Yang, Jian-Hong Zhong, Le-Qun Li
The safety and efficacy of perioperative antiviral therapy for patients with hepatitis B virus related hepatocellular carcinoma and low serum levels of hepatitis B virus DNA are unknown. This retrospective study compared serum levels of hepatitis B virus DNA, liver function, morbidity, and length of hospital stay between patients who underwent hepatic resection alone and patients who received entecavir therapy before and after resection (n = 44 in each group). Propensity score matching was used to reduce confounding due to baseline differences between the groups...
August 1, 2017: Oncotarget
https://www.readbyqxmd.com/read/28875955/efficacy-of-real-world-entecavir-therapy-in-treatment-na%C3%A3-ve-chronic-hepatitis-b-patients
#5
Yan-Di Xie, Hui Ma, Bo Feng, Lai Wei
Background: Entecavir (ETV) has been shown to be effective in randomized controlled trials in highly selected patients with hepatitis B virus (HBV) infection. This study aimed to evaluate the efficacy of ETV in chronic hepatitis B (CHB) patients in the real-world setting. Methods: A total of 233 treatment-naïve, CHB patients who received at least 12 months of ETV treatment were included in this retrospective study. Rates of virological response (VR), hepatitis B s antigen (HBsAg) loss, hepatitis B e antigen (HBeAg) clearance/seroconversion, virological breakthrough, cirrhosis, and hepatocellular carcinoma were evaluated...
September 20, 2017: Chinese Medical Journal
https://www.readbyqxmd.com/read/28870671/relationship-between-serum-hbv-rna-levels-and-intrahepatic-viral-as-well-as-histologic-activity-markers-in-entecavir-treated-patients
#6
Jing Wang, Yiqi Yu, Guojun Li, Chuan Shen, Zhefeng Meng, Jianming Zheng, Yanhong Jia, Shaolong Chen, Xiao Zhang, MengQi Zhu, Jiangjiang Zheng, Zhangzhang Song, Jing Wu, Lingyun Shao, Peiyu Qian, Xiaona Mao, Xuanyi Wang, Yuxian Huang, Caiyan Zhao, Jiming Zhang, Chao Qiu, Wenhong Zhang
BACKGROUND: In diagnostics, serum hepatitis B virus (HBV)-RNA levels are valuable when the HBV-DNA load in circulation is effectively suppressed by nucleos(t)ide analogue (NUC) therapy. This study aimed to determine the intrahepatic viral replication activity reflected in serum HBV-RNA and whether HBV-RNA contributes to liver histological changes in NUC-treated patients. METHODS: A cross-sectional set of serum and liver biopsy samples was obtained from entecavir-treated patients with undetectable levels of serum HBV-DNA...
September 1, 2017: Journal of Hepatology
https://www.readbyqxmd.com/read/28870666/tenofovir-alafenamide-as-a-rescue-therapy-in-a-cirrhotic-hbv-patient-with-a-hystory-of-fanconi-syndrome-and-multidrug-resistance-a-case-report
#7
Glenda Grossi, Alessandro Loglio, Floriana Facchetti, Marta Borghi, Roberta Soffredini, Enrico Galmozzi, Giovanna Lunghi, Anuj Gaggar, Pietro Lampertico
Tenofovir disoproxil fumarate (TDF) is a recommended first-line therapy for both naïve and experienced chronic hepatitis B (CHB) patients although reduced estimated glomerular filtration rate (eGFR), hypophosphatemia, hyperphosphaturia and Fanconi syndrome have been reported in some patients. Entecavir (ETV) could be considered as a rescue therapy for TDF treated patients developing renal dysfunction, though patients with prior history of treatment with Lamivudine (LAM) can develop ETV resistance strains which can lead to potentially severe hepatitis flares...
September 1, 2017: Journal of Hepatology
https://www.readbyqxmd.com/read/28870025/clinical-characteristics-of-patients-with-chronic-hepatitis-b-who-developed-genotypic-resistance-to-entecavir-real-life-experience
#8
Hong Joo Kim, Yong Kyun Cho, Woo Kyu Jeon, Byung Ik Kim
Background/Aims: Clinical characteristics of patients with chronic hepatitis B (CHB) who developed genotypic resistance to entecavir (ETV) were compared to those without resistance. Methods: Two hundred fifty eight CHB patients who underwent ETV treatment in our institution from July 2007 to May 2013 were included. Results: Eight (3.1%) patients developed genotypic resistance to ETV during the follow-up period. The patterns of genotypic resistance to ETV were as follows: L180M + M204V + S202G (n=3); M204I + V173M (n=1); I169V + V173M (n=1); L180M + M204V + V173L (n=1); L180M + M204V + V173L + M250V (n=1); M204I + V214A + P237H (n=1)...
September 5, 2017: Clinical and Molecular Hepatology
https://www.readbyqxmd.com/read/28857411/trajectories-of-serum-hepatitis-b-surface-antigen-kinetics-in-patients-with-chronic-hepatitis-b-receiving-long-term-nucleos-t-ide-analogue-therapy
#9
Wei-Fan Hsu, Chuen-Fei Chen, Hsueh-Chou Lai, Wen-Pang Su, Chia-Hsin Lin, Po-Heng Chuang, Sheng-Hung Chen, Ching-Hsiang Chen, Hung-Wei Wang, Guan-Tarn Huang, Cheng-Yuan Peng
BACKGROUND & AIMS: The kinetics of serum hepatitis B surface antigen (HBsAg) levels during long-term nucleos(t)ide analogue (NA) therapy in chronic hepatitis B (CHB) patients remains unclear. We investigated the patterns of serum HBsAg kinetics and their association with therapeutic outcomes in genotype B- or C-infected CHB patients receiving long-term NA therapy. METHODS: We enrolled 329 treatment-naive CHB patients receiving NA therapy for >5 years to analyse the kinetic patterns by using group-based trajectory models (GBTMs)...
August 31, 2017: Liver International: Official Journal of the International Association for the Study of the Liver
https://www.readbyqxmd.com/read/28854883/addition-of-nucleoside-analogues-to-peg-ifn%C3%AE-2a-enhances-virological-response-in-chronic-hepatitis-b-patients-without-early-response-to-peg-ifn%C3%AE-2a-a-randomized-controlled-trial
#10
Yan Xu, Xu Wang, Zhenhua Liu, Changyu Zhou, Wenqian Qi, Jian Jiao, Fan Yu, Honghua Guo, Ping Zhao, Jiangbin Wang
BACKGROUND: Current treatments for chronic hepatitis B (CHB) include pegylated interferon alpha (PEG-IFN-α) which is an immune modulator, and nucleos(t)ide analogs (NAs) which directly inhibit HBV DNA polymerase. With the limited efficacy of PEG-IFN-α and prolonged treatment periods associated with NAs, there is an urgent need for novel therapeutic strategies, especially for patients with a poor early response to anti-viral therapy. METHODS: In this study, 178 patients with chronic hepatitis B (n = 131) and compensated (n = 47) HBV-induced cirrhosis were enrolled, 120 patients with HBeAg (+)...
August 30, 2017: BMC Gastroenterology
https://www.readbyqxmd.com/read/28851562/viral-load-affects-the-immune-response-to-hbv-in-mice-with-humanized-immune-system-and-liver
#11
Mathilde Dusséaux, Guillemette Masse-Ranson, Sylvie Darche, James Ahodantin, Yan Li, Oriane Fiquet, Elodie Beaumont, Pierrick Moreau, Lise Rivière, Christine Neuveut, Patrick Soussan, Philippe Roingeard, Dina Kremsdorf, James P Di Santo, Helene Strick-Marchand
BACKGROUND & AIMS: Hepatitis B virus (HBV) infects hepatocytes, but the mechanisms of the immune response against the virus, and how it affects disease progression, are unclear. METHODS: We performed studies with BALB/c Rag2(-/-)Il2rg(-/-)Sirpa(NOD)Alb-uPA(tg/tg) mice, stably engrafted with human hepatocytes (HUHEP) with or without a human immune system (HIS). HUHEP and HIS-HUHEP mice were given an intraperitoneal injection of HBV. Mononuclear cells were isolated from spleen and liver for analysis by flow cytometry...
August 26, 2017: Gastroenterology
https://www.readbyqxmd.com/read/28851305/nephrolithiasis-and-osteomalacia-associated-with-adefovir-induced-fanconi-syndrome-in-a-patient-with-hepatitis-b
#12
Jueying Lin, Yufeng Zhuo, Dongdong Zhang
BACKGROUND: An increasing number of case reports suggest that acquired renal Fanconi syndrome may be associated with prolonged use of adefovir against hepatitis B virus. Renal Fanconi syndrome is an uncommon disease, and its complication with nephrolithiasis is quite rare. Herein, we report a rare coexistence of nephrolithiasis and acquired renal Fanconi syndrome in a chronic hepatitis B-positive patient with prolonged adefovir therapy. CASE PRESENTATION: The patient presented with osteomalacia and nephrolithiasis...
August 29, 2017: BMC Nephrology
https://www.readbyqxmd.com/read/28850029/liver-safety-of-non-tumour-necrosis-factor-inhibitors-in-rheumatic-patients-with-past-hepatitis-b-virus-infection-an-observational-controlled-long-term-study
#13
Ioannis Papalopoulos, Antonis Fanouriakis, Nikolaos Kougkas, Irini Flouri, George Sourvinos, George Bertsias, Argyro Repa, Nestor Avgoustidis, Prodromos Sidiropoulos
OBJECTIVES: The risk of hepatitis B virus (HBV) reactivation with non-tumour necrosis factor inhibitor (non-TNFi) biologic agents in patients with rheumatic diseases and past HBV infection has not been definively elucidated. We assessed the comparative safety of non-TNFi and TNFi biologic agents in such patients in real-life clinical settings. METGODS: We carried out a retrospective cohort study from the Department of Rheumatology, University Hospital of Heraklion...
August 28, 2017: Clinical and Experimental Rheumatology
https://www.readbyqxmd.com/read/28797777/comparison-of-the-efficacy-of-tenofovir-versus-tenofovir-plus-entecavir-in-the-treatment-of-chronic-hepatitis-b-in-patients-with-poor-efficacy-of-entecavir-a-systematic-review-and-meta-analysis
#14
REVIEW
Jun Chen, Shu-Shan Zhao, Xiao-Xiao Liu, Ze-Bing Huang, Yan Huang
PURPOSE: This study aimed to compare the efficacy between tenofovir disoproxil fumarate (TDF) and TDF plus entecavir (ETV) combination therapy in patients with chronic hepatitis B (CHB) with a poor response to ETV. METHODS: We searched the China National Knowledge Infrastructure (CNKI), PubMed, EMBASE, and SCOPE libraries for articles using the keywords chronic hepatitis B virus or CHB or HBV, entecavir or ETV, and tenofovir or TDF. FINDINGS: Five studies (from CNKI and PubMed) with a total of 408 patients met the inclusion criteria: 212 patients in the TDF group and 196 patients in the TDF plus ETV group...
August 7, 2017: Clinical Therapeutics
https://www.readbyqxmd.com/read/28774415/new-treatments-to-reach-functional-cure-virological-approaches
#15
REVIEW
David Durantel
Current therapies of chronic hepatitis B (CHB) remain limited to pegylated-interferon-alpha (pegIFN-α) or any of the five approved nucleos(t)ide analogues (NA). If viral suppression can be achieved in the majority of patients with the high-barrier-to-resistance new-generation of NA, i.e. entecavir and tenofovir, HBsAg loss is achieved by PEG-IFN-α and/or NA in only 10% of patients, after a 5-year follow-up. Attempts to improve the response by administering two different NA or a combination of NA and PEG-IFN-α have not provided a dramatic increase in the rate of "functional cure"...
June 2017: Best Practice & Research. Clinical Gastroenterology
https://www.readbyqxmd.com/read/28768965/reactivation-of-occult-hepatitis-b-virus-infection-27-months-after-the-end-of-chemotherapy-including-rituximab-for-malignant-lymphoma
#16
Junichi Muraishi, Michihiko Shibata, Yuichi Honma, Masaaki Hiura, Shintaro Abe, Masaru Harada
A 68-year-old man with occult hepatitis B virus (HBV) infection was diagnosed with malignant lymphoma and achieved complete remission after treatment with a chemotherapy regimen including rituximab for 5 months. Entecavir (ETV) was also used during and after chemotherapy and was ended at 14 months after chemotherapy. However, reactivation of HBV was observed in blood tests, which showed not only elevation of HBV-DNA but also HBsAg and HBeAg, at 27 months after the end of chemotherapy. After restarting ETV, the HBV-DNA levels immediately subsided...
2017: Internal Medicine
https://www.readbyqxmd.com/read/28757048/a-long-term-multicenter-study-entecavir-versus-tenofovir-in-treatment-of-nucleos-t-ide-analogue-naive-chronic-hepatitis-b-patients
#17
Bircan Kayaaslan, Esragul Akinci, Alpay Ari, Zeliha Kocak Tufan, Saygın Nayman Alpat, Ozgur Gunal, Selma Tosun, Rahmet Guner, Fehmi Tabak
BACKGROUND: Entecavir (ETV) and tenofovir disoproxil fumarat (TDF) are the two first-line therapies recommended in the treatment of chronic hepatitis B because of having potent antiviral effect and high genetic barriers against resistance. We aimed to compare efficacy of these drugs and to evaluate predictors of viral suppression. METHODS: This multicenter retrospective study was conducted in nucleos(t)ide analogue-naive chronic hepatitis B (CHB) patients from different 6 centers...
July 27, 2017: Clinics and Research in Hepatology and Gastroenterology
https://www.readbyqxmd.com/read/28752768/effects-of-antiviral-therapy-in-patients-with-chronic-hepatitis-b-and-cirrhosis
#18
Masako Okada, Masaru Enomoto, Norifumi Kawada, Mindie H Nguyen
Hepatitis B virus (HBV) infection is the major cause of cirrhosis worldwide. The ultimate goal of current antiviral treatments for chronic hepatitis B (nucleos(t)ide analogs and interferon-α) is to prevent the development of end-stage liver diseases. Areas covered: We present a review of the current literature on antiviral therapy in patients with chronic hepatitis B and cirrhosis. Medline search was performed to identify relevant literature from 1993 through January of 2017. Expert commentary: One randomized controlled trial and a number of observational studies have shown that nucleos(t)ide analogs can decrease the incidence of hepatocellular carcinoma (HCC) in chronic hepatitis B patients with advanced fibrosis...
August 7, 2017: Expert Review of Gastroenterology & Hepatology
https://www.readbyqxmd.com/read/28750917/predictive-role-of-serum-hbsag-and-hbcrag-kinetics-in-patients-with-hbeag-negative-chronic-hepatitis-b-receiving-pegylated-interferon-based-therapy
#19
Natthaya Chuaypen, Nawarat Posuwan, Salyavit Chittmittraprap, Nattiya Hirankarn, Sombat Treeprasertsuk, Yasuhito Tanaka, Noboru Shinkai, Yong Poovorawan, Pisit Tangkijvanich
OBJECTIVES: To investigate the role of serum hepatitis B core-related antigen (HBcrAg) kinetics in predicting long-term outcome of pegylated interferon (PEG-IFN)-based therapy in patients with HBeAg-negative chronic hepatitis B (CHB). METHODS: 121 Thai patients with HBeAg-negative CHB recruited from a previous randomized trial of 48-week PEG-IFN alone or combined with entecavir were enrolled. HBsAg and HBcrAg levels were serially examined. Paired biopsies at baseline and post-treatment were assessed for intrahepatic cccDNA...
July 24, 2017: Clinical Microbiology and Infection
https://www.readbyqxmd.com/read/28746158/lactate-serum-concentrations-during-treatment-with-nucleos-t-ide-analogues-in-hepatitis-b-with-or-without-cirrhosis
#20
Christos Triantos, Maria Kalafateli, Ioanna Aggeletopoulou, Martha Mandellou, Stelios Assimakopoulos, Paraskevi Tselekouni, Dimitra Taprantzi, Giorgos Tsiaoussis, Georgia Vourli, Evangelos D Anastassiou, Charalambos Gogos, Chrisoula Labropoulou-Karatza, Konstantinos Thomopoulos
OBJECTIVE: The aim of this study is to evaluate the clinical implications of lactate concentrations in patients with hepatitis B with or without cirrhosis during treatment with nucleos(t)ide analogues. PATIENTS AND METHODS: One hundred and seven consecutive patients with chronic hepatitis B and median age 57 (24-85) years were prospectively included. Lactate concentrations were measured at baseline and at 12, 24, 36, 48, and 60 months following the baseline measurements...
September 2017: European Journal of Gastroenterology & Hepatology
keyword
keyword
2107
1
2
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read
×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"